{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=COVID-19+mRNA+vaccine&page=3",
    "query": {
      "intervention": "COVID-19 mRNA vaccine",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 148,
    "total_pages": 15,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=COVID-19+mRNA+vaccine&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=COVID-19+mRNA+vaccine&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T02:49:44.634Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04818892",
      "title": "Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "IBD",
        "Covid19 Vaccine"
      ],
      "interventions": [
        {
          "name": "Serological Assay for SARS-CoV-2",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 222,
      "start_date": "2021-03-26",
      "completion_date": "2022-11-11",
      "has_results": false,
      "last_update_posted_date": "2022-12-07",
      "last_synced_at": "2026-10-09T02:49:44.634Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04818892"
    },
    {
      "nct_id": "NCT06038617",
      "title": "Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fever After Vaccination",
        "Fever",
        "Seizures Fever"
      ],
      "interventions": [
        {
          "name": "mRNA COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Routine Childhood Vaccinations",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "4 Years",
        "sex": "ALL",
        "summary": "6 Months to 4 Years"
      },
      "enrollment_count": 347,
      "start_date": "2023-10-30",
      "completion_date": "2025-07-25",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-10-09T02:49:44.634Z",
      "location_count": 5,
      "location_summary": "Oakland, California • Atlanta, Georgia • New York, New York + 2 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06038617"
    },
    {
      "nct_id": "NCT04977479",
      "title": "The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Allergic Reaction"
      ],
      "interventions": [
        {
          "name": "Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Pfizer-BioNTech COVID-19 Vaccine, Bivalent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "16 Years to 69 Years"
      },
      "enrollment_count": 20,
      "start_date": "2021-09-08",
      "completion_date": "2023-02-22",
      "has_results": true,
      "last_update_posted_date": "2023-10-16",
      "last_synced_at": "2026-10-09T02:49:44.634Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04977479"
    },
    {
      "nct_id": "NCT05875701",
      "title": "Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "NVX-CoV2373",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 rS antigen/Matrix-M Adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 147,
      "start_date": "2023-03-28",
      "completion_date": "2023-11-11",
      "has_results": true,
      "last_update_posted_date": "2025-06-26",
      "last_synced_at": "2026-10-09T02:49:44.634Z",
      "location_count": 5,
      "location_summary": "Austin, Texas • Fort Worth, Texas • Plano, Texas + 1 more",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        },
        {
          "city": "Plano",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05875701"
    },
    {
      "nct_id": "NCT05436834",
      "title": "A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "mRNA-1273.214",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.815",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "6 Months to 5 Years"
      },
      "enrollment_count": 1807,
      "start_date": "2022-06-21",
      "completion_date": "2025-10-20",
      "has_results": false,
      "last_update_posted_date": "2025-11-26",
      "last_synced_at": "2026-10-09T02:49:44.634Z",
      "location_count": 48,
      "location_summary": "Bessemer, Alabama • Banning, California • Montebello, California + 38 more",
      "locations": [
        {
          "city": "Bessemer",
          "state": "Alabama"
        },
        {
          "city": "Banning",
          "state": "California"
        },
        {
          "city": "Montebello",
          "state": "California"
        },
        {
          "city": "Paramount",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05436834"
    },
    {
      "nct_id": "NCT05960097",
      "title": "A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "CV0701 mRNA COVID-19 Vaccine (Low dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0701 mRNA COVID-19 Vaccine (Medium dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0701 mRNA COVID-19 Vaccine (High dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0601 mRNA COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0801 mRNA COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 692,
      "start_date": "2023-08-01",
      "completion_date": "2024-08-30",
      "has_results": true,
      "last_update_posted_date": "2025-10-23",
      "last_synced_at": "2026-10-09T02:49:44.634Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • Hollywood, Florida • Peoria, Illinois",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05960097"
    },
    {
      "nct_id": "NCT04887948",
      "title": "Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Disease",
        "COVID-19",
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "20-valent pneumococcal conjugate vaccine (20vPnC)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 570,
      "start_date": "2021-05-20",
      "completion_date": "2021-12-08",
      "has_results": true,
      "last_update_posted_date": "2022-12-14",
      "last_synced_at": "2026-10-09T02:49:44.634Z",
      "location_count": 27,
      "location_summary": "Anaheim, California • Walnut Creek, California • Coral Gables, Florida + 21 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04887948"
    },
    {
      "nct_id": "NCT06441955",
      "title": "Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COVID-19, Long Haul"
      ],
      "interventions": [
        {
          "name": "Ritonavir-Boosted Nirmatrelvir (Paxlovid)",
          "type": "DRUG"
        },
        {
          "name": "Physiological Evaluation",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Moderna COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biopsychological",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Behavioral (e.g., Psychotherapy, Lifestyle Counseling)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Genetic (including gene transfer, stem cell and recombinant DNA)",
          "type": "GENETIC"
        },
        {
          "name": "Multidisciplinary approach",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "BIOLOGICAL",
        "BEHAVIORAL",
        "GENETIC",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Well- Konnect Healthcare Services and Research Firm",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 100,
      "start_date": "2024-03-01",
      "completion_date": "2030-09-30",
      "has_results": false,
      "last_update_posted_date": "2024-11-27",
      "last_synced_at": "2026-10-09T02:49:44.634Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06441955"
    },
    {
      "nct_id": "NCT05020145",
      "title": "COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Immunocompromised",
        "Immunosuppressed",
        "Covid-19",
        "SARS-COV-2",
        "SARS-COV-2 Infection",
        "Breakthrough Infection"
      ],
      "interventions": [
        {
          "name": "BNT162b2 (Tozinameran)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1277747,
      "start_date": "2021-08-25",
      "completion_date": "2021-12-17",
      "has_results": true,
      "last_update_posted_date": "2024-02-12",
      "last_synced_at": "2026-10-09T02:49:44.634Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05020145"
    },
    {
      "nct_id": "NCT04843774",
      "title": "Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "SARS-COV-2 mRNA Vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 64,
      "start_date": "2021-04-20",
      "completion_date": "2023-04-18",
      "has_results": false,
      "last_update_posted_date": "2023-11-08",
      "last_synced_at": "2026-10-09T02:49:44.634Z",
      "location_count": 2,
      "location_summary": "Denver, Colorado • New York, New York",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04843774"
    }
  ]
}